Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy. 2024

Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
Department of Medical Oncology, Hospital General Universitario Gregorio Marañón Instituto de Investigacion Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid., Madrid, Spain.

BACKGROUND Stromal tumor-infiltrating lymphocytes (sTILs) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in setting of anthracycline-based chemotherapy. Impact of sTILs on refining outcomes beyond prognostic information provided by pCR in anthracycline-free neoadjuvant chemotherapy (NAC) is not known. METHODS This is pooled analysis of two studies where patients with stage I(T>1cm)-III TNBC received carboplatin(AUC 6) plus docetaxel(75mg/m2) (CbD) NAC. sTILs were evaluated centrally on pre-treatment H&E slides using standard criteria. Cox regression analysis was used to examine effect on event-free survival (EFS) and overall survival (OS). RESULTS Among 474 patients, 44% had node-positive disease. Median sTILs were 5% (range 1%-95%), and 32% of patients had ≥30% sTILs. pCR rate was 51%. On multivariable analysis, T stage (OR=2.08,p=0.007), nodal status (OR=1.64,p=0.035), and sTILs (OR=1.10,p=0.011) were associated with pCR. On multivariate analysis, nodal status (HR=0.46,p=0.008), pCR(HR=0.20,p<0.001), and sTILs(HR=0.95,p=0.049) were associated with OS. At 30% cut-point, sTILs stratified outcomes in stage III disease, 5-year OS 86% vs 57% in ≥30% vs <30% sTILs (HR=0.29,p=0.014), and numeric trend in stage II, 5-year OS 93% vs 89% in ≥30% vs <30% sTILs (HR=0.55,p=0.179). Among stage II-III patients with pCR, EFS was better in those with ≥30% sTILs (HR=0.16,p=0.047). CONCLUSIONS sTILs density was independent predictor of OS beyond clinicopathologic features and pathologic response in TNBC patients treated with anthracycline-free CbD chemotherapy. Notably, sTILs density stratified outcomes beyond TNM stage and pathologic response. These findings highlight role of sTILs in patient selection/stratification for neo/adjuvant escalation and de-escalation strategies.

UI MeSH Term Description Entries

Related Publications

Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
October 2016, World journal of clinical oncology,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
April 2012, Breast cancer research and treatment,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
January 2022, Journal of cancer research and therapeutics,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
January 2017, Ecancermedicalscience,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
April 2020, Anticancer research,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
April 2024, JAMA,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
January 2011, Breast cancer research : BCR,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
December 2014, Breast cancer research and treatment,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
January 2022, The Gulf journal of oncology,
Miguel Martín, and Rachel Yoder, and Roberto Salgado, and Maria Del Monte-Millán, and Enrique L Alvarez, and Isabel Echavarría, and Joshua M Staley, and Anne P O'Dea, and Lauren E Nye, and Shane R Stecklein, and Coralia Bueno Muiño, and Yolanda Jerez-Gilarranz, and María Cebollero, and Oscar Bueno, and Jose Ángel Garcia-Saenz, and Fernando Moreno, and Uriel Bohn, and Henry Gomez, and Tatiana Massarrah, and Qamar J Khan, and Andrew K Godwin, and Sara López-Tarruella, and Priyanka Sharma
September 2023, Oncology letters,
Copied contents to your clipboard!